Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: A systematic review

Cancer Epidemiology Biomarkers and Prevention

Volumn 22, Issue 11, 2013, Pages 1931-1943

  Gierisch, Jennifer M ^a,b,c   Coeytaux, Remy R ^b,d   Urrutia, Rachel Peragallo ^h   Havrilesky, Laura J ^e,g   Moorman, Patricia G ^d   Lowery, William J ^e   Dinan, Michaela ^b   McBroom, Amanda J ^b   Hasselblad, Vic ^f   Sanders, Gillian D ^b,c   Myers, Evan R ^e  

^a DURHAM VA MEDICAL CENTER   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d Departments of Community and Family Medicine   (United States)

^e Kaiser Permanente Northern California   (United States)

^f DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g DUKE CANCER INSTITUTE   (United States)

^h UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ORAL CONTRACEPTIVE AGENT;

ALCOHOL CONSUMPTION; BREAST CANCER; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; COCHRANE LIBRARY; COLORECTAL CANCER; CONTRACEPTION; DISEASE ASSOCIATION; DRUG EXPOSURE; ENDOMETRIUM CANCER; HUMAN; LONG TERM EXPOSURE; MEDLINE; ORAL CONTRACEPTIVE USE; OUTCOME ASSESSMENT; PAPILLOMAVIRUS INFECTION; PERSISTENT INFECTION; PHYSICAL INACTIVITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SMOKING; SYSTEMATIC REVIEW; THROMBOEMBOLISM; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU;

BREAST NEOPLASMS; CONTRACEPTIVES, ORAL; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; OVARIAN NEOPLASMS; UTERINE CERVICAL NEOPLASMS;

EID: 84887275425     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-13-0298     Document Type: Review

References (108)

1. Mosher WD, Jones J. Use of contraception in the United States: 1982-2008. Vital Health Stat 23 2010;1-44.
2. Dinger J, Do Minh T, Buttmann N, Bardenheuer K. Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen. Obstet Gynecol 2011;117:33-40.
3. Dinger JC, Cronin M, Mohner S, Schellschmidt I, Minh TD, Westhoff C. Oral contraceptive effectiveness according to body mass index, weight, age, and other factors. Am J Obstet Gynecol 2009;201:263. e1-9.
4. Spencer AL, Bonnema R, McNamara MC. Helping women choose appropriate hormonal contraception: update on risks, benefits, and indications. Am J Med 2009;122:497-506.
5. Haider A, Shaw JC. Treatment of acne vulgaris. JAMA 2004;292: 726-35.
6. Lindh I, Ellstrom AA, Milsom I. The effect of combined oral contraceptives and age on dysmenorrhoea: An epidemiological study. Hum Reprod 2012;27:676-82.
7. La Vecchia C, Altieri A, Franceschi S, Tavani A. Oral contraceptives and cancer: An update. Drug Saf 2001;24:741-54.
8. Gillum LA, Mamidipudi SK, Johnston SC. Ischemic stroke risk with oral contraceptives: A meta-analysis. JAMA 2000;284:72-8.
9. Gillum LA, Mamidipudi SK, Johnston SC. Review: current oral contraceptive use increases the risk for ischaemic stroke. Evidence- Based Med 2001;6:60.
10. Anonymous. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995;346:1575-82.
11. Bosetti C, Bravi F, Negri E, La Vecchia C. Oral contraceptives and colorectal cancer risk: A systematic review and meta-analysis. Hum Reprod Update 2009;15:489-98.
12. Anonymous. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1996;347:1713-27.
13. Smith JS, Green J, Berrington de Gonzalez A, Appleby P, Peto J, Plummer M, et al. Cervical cancer and use of hormonal contraceptives: A systematic review. Lancet 2003;361:1159-67.
14. Cibula D, Gompel A, Mueck AO, La Vecchia C, Hannaford PC, Skouby SO, et al. Hormonal contraception and risk of cancer. Hum Reprod Update 2010;16:631-50.
15. Cibula D, Zikan M, Dusek L, Majek O. Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: A metaanalysis. Expert Rev Anticancer Ther 2011;11:1197-207.
16. Marchbanks PA, McDonald JA, Wilson HG, Folger SG, Mandel MG, Daling JR, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med 2002;346:2025-32.
17. Dolle JM, Daling JR, White E, Brinton LA, Doody DR, Porter PL, et al. Risk factors for triple-negative breast cancer in women under the age of 45 years. Cancer Epidemiol Biomarkers Prev 2009;18:1157-66.
18. Mueck AO, Seeger H, Rabe T. Hormonal contraception and risk of endometrial cancer: A systematic review. Endocr Relat Cancer 2010; 17:R263-71.
19. Beral V, Doll R, Hermon C, Peto R, Reeves G. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23, 257 women with ovarian cancer and 87, 303 controls. Lancet 2008;371:303-14.
20. Havrilesky LJ, Gierisch JM, Moorman PG, Coeytaux RR, Peragallo Urrutia R, Lowery WJ, et al. Oral contraceptive use for the primary prevention of ovarian cancer. Evidence Report #101. (Prepared by the Duke Evidence-based Practice Center under Contract No. 290- 2007-10066-I.) AHRQ Publication No. 13-EHC033-EF. Rockville, MD: Agency for Healthcare Research and Quality. Available from: http://www.effectivehealthcare.ahrq.gov/ehc/products/416/1528/ cancer-ovarian-contraceptives-report-130607.pdf.
21. Moorman PG, Calingaert B, Palmieri RT, Iversen ES, Bentley RC, Halabi S, et al. Hormonal risk factors for ovarian cancer in premenopausal and postmenopausal women. Am J Epidemiol 2008;167: 1059-69.
22. Agency for Healthcare Research and Quality. Methods guide for effectiveness and comparative effectiveness reviews. AHRQ Publication No. 10(12)-EHC063-EF. Rockville, MD: Agency for Healthcare Research and Quality; 2012. Available from: www.effectivehealthcare.ahrq.gov.
23. Borenstein M, Hedges L, Higgins J, Rothstein H. Comprehensive Meta-analysis Version 2. Englewood, NJ: Biostat; 2005.
24. National Cancer Institute. Surveillance Research-Cancer Control and Population Sciences. DevCan: Probability of Developing or Dying of Cancer. [cited 2013 Jan 3]; Available from: http://surveillance.cancer.gov/devcan/.
25. Centers for Disease Control and Prevention. National Survey of Family Growth. 2006-2010 NSFG: Public Use Data Files, Codebooks, and Documentation. [cited 2013 Jan 3]; Available from: http://www.cdc.gov/nchs/nsfg/nsfg-2006-2010- puf.htm.
26. Owens DK, Lohr KN, Atkins D, Treadwell JR, Reston JT, Bass EB, et al.AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions-Agency for Healthcare Research and Quality and the Effective Health-Care Program. J Clin Epidemiol 2010;63:513-23.
27. Shapiro S, Rosenberg L, Hoffman M, Truter H, Cooper D, Rao S, et al. Risk of breast cancer in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen contraceptives. Am J Epidemiol 2000;151:396-403.
28. Van Hoften C, Burger H, Peeters PH, Grobbee DE, Van Noord PA, Leufkens HG. Long-term oral contraceptive use increases breast cancer risk in women over 55 years of age: The DOM cohort. Int J Cancer 2000;87:591-4.
29. Gomes AL, Guimaraes MD, Gomes CC, Chaves IG, Gobbi H, Camargos AF. Risk factors for breast cancer among pre- or post-menopausal women in Belo Horizonte, Brazil. Gynecol Obstet Invest 2001;52:173-9.
30. Moorman PG, Millikan RC, Newman B. Oral contraceptives and breast cancer among African-American women and white women. J Natl Med Assoc 2001;93:329-34.
31. Heimdal K, Skovlund E, Moller P. Oral contraceptives and risk of familial breast cancer. Cancer Detect Prev 2002;26:23-7.
32. Narod SA, Dube MP, Klijn J, Lubinski J, Lynch HT, Ghadirian P, et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2002;94:1773-9.
33. Althuis MD, Brogan DD, Coates RJ, Daling JR, Gammon MD, Malone KE, et al. Breast cancers among very young premenopausal women (United States). Cancer Causes Control 2003;14:151-60.
34. Althuis MD, Brogan DR, Coates RJ, Daling JR, Gammon MD, Malone KE, et al. Hormonal content and potency of oral contraceptives and breast cancer risk among young women. Br J Cancer 2003;88:50-7.
35. Newcomer LM, Newcomb PA, Trentham-Dietz A, Longnecker MP, Greenberg ER. Oral contraceptive use and risk of breast cancer by histologic type. Int J Cancer 2003;106:961-4.
36. Norman SA, Berlin JA, Weber AL, Strom BL, Daling JR, Weiss LK, et al. Combined effect of oral contraceptive use and hormone replacement therapy on breast cancer risk in postmenopausal women. Cancer Causes Control 2003;14:933-43.
37. Suter NM, Malone KE, Daling JR, Doody DR, Ostrander EA. Androgen receptor (CAG)n and (GGC)n polymorphisms and breast cancer risk in a population-based case-control study of young women. Cancer Epidemiol Biomarkers Prev 2003;12:127-35.
38. Fowke JH, Shu XO, Dai Q, Jin F, Cai Q, Gao YT, et al. Oral contraceptive use and breast cancer risk: modification by NAD(P)H: quinone oxoreductase (NQO1) genetic polymorphisms. Cancer Epidemiol Biomarkers Prev 2004;13:1308-15.
39. Jernstrom H, Loman N, Johannsson OT, Borg A, Olsson H. Impact of teenage oral contraceptive use in a population-based series of earlyonset breast cancer cases who have undergone BRCA mutation testing. Eur J Cancer 2005;41:2312-20.
40. Milne RL, Knight JA, John EM, Dite GS, Balbuena R, Ziogas A, et al. Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev 2005;14:350-6.
41. Gronwald J, Byrski T, Huzarski T, Cybulski C, Sun P, Tulman A, et al. Influence of selected lifestyle factors on breast and ovarian cancer risk inBRCA1 mutation carriers from Poland. Breast Cancer Res Treat 2006;95:105-9.
42. Haile RW, Thomas DC, McGuire V, Felberg A, John EM, Milne RL, et al. BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50. Cancer Epidemiol Biomarkers Prev 2006;15:1863-70.
43. Rosenberg LU, Magnusson C, Lindstrom E, Wedren S, Hall P, Dickman PW. Menopausal hormone therapy and other breast cancer risk factors in relation to the risk of different histological subtypes of breast cancer: A case-control study. Breast Cancer Res 2006;8:R11.
44. MaH, Bernstein L, Ross RK, Ursin G. Hormone-related risk factors for breast cancer in women under age 50 years by estrogen and progesterone receptor status: results from a case-control and a casecase comparison. Breast Cancer Res 2006;8:R39.
45. Faheem M, Khurram M, Jafri IA, Mehmood H, Hasan Z, Iqbal GS, et al. Risk factors for breast cancer in patients treated at NORI Hospital, Islamabad. J Pak Med Assoc 2007;57:242-5.
46. Folger SG, Marchbanks PA, McDonald JA, Bernstein L, Ursin G, Berlin JA, et al. Risk of breast cancer associated with short-term use of oral contraceptives. Cancer Causes Control 2007;18:189-98.
47. Nichols HB, Trentham-Dietz A, Egan KM, Titus-Ernstoff L, Hampton JM, Newcomb PA. Oral contraceptive use and risk of breast carcinoma in situ. Cancer Epidemiol Biomarkers Prev 2007;16: 2262-8.
48. Shantakumar S, Terry MB, Paykin A, Teitelbaum SL, Britton JA, Moorman PG, et al. Age and menopausal effects of hormonal birth control and hormone replacement therapy in relation to breast cancer risk. Am J Epidemiol 2007;165:1187-98.
49. Sweeney C, Giuliano AR, Baumgartner KB, Byers T, Herrick JS, Edwards SL, et al. Oral, injected and implanted contraceptives and breast cancer risk among U.S. Hispanic and non-Hispanic white women. Int J Cancer 2007;121:2517-23.
50. Figueiredo JC, Bernstein L, Capanu M, Malone KE, Lynch CF, Anton- Culver H, et al. Oral contraceptives, postmenopausal hormones, and risk of asynchronous bilateral breast cancer: The WECARE Study Group. J Clin Oncol 2008;26:1411-8.
51. Lee E, Ma H, McKean-Cowdin R, Van Den Berg D, Bernstein L, Henderson BE, et al. Effect of reproductive factors and oral contraceptives on breast cancer risk in BRCA1/2 mutation carriers and noncarriers: results from a population-based study. Cancer Epidemiol Biomarkers Prev 2008;17:3170-8.
52. Nyante SJ, Gammon MD, Malone KE, Daling JR, Brinton LA. The association between oral contraceptive use and lobular and ductal breast cancer in young women. Int J Cancer 2008;122: 936-41.
53. Rosenberg L, Zhang Y, Coogan PF, Strom BL, Palmer JR. A casecontrol study of oral contraceptive use and incident breast cancer. Am J Epidemiol 2009;169:473-9.
54. Phillips LS, Millikan RC, Schroeder JC, Barnholtz-Sloan JS, Levine BJ. Reproductive and hormonal risk factors for ductal carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev 2009;18: 1507-14.
55. Figueiredo JC, Haile RW, Bernstein L, Malone KE, Largent J, Langholz B, et al. Oral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: The WECARE Study. Breast Cancer Res Treat 2010;120:175-83.
56. Lumachi F, Frigo AC, Basso U, Tombolan V, Ermani M. Estrogen therapy and risk of breast cancer in postmenopausal women: A casecontrol study and results of a multivariate analysis. Menopause 2010;17:524-8.
57. Ma H, Wang Y, Sullivan-Halley J, Weiss L, Marchbanks PA, Spirtas R, et al. Use of four biomarkers to evaluate the risk of breast cancer subtypes in the women's contraceptive and reproductive experiences study. Cancer Res 2010;70:575-87.
58. Grabrick DM, Hartmann LC, Cerhan JR, Vierkant RA, Therneau TM, Vachon CM, et al. Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer. JAMA 2000;284: 1791-8.
59. Kumle M, Weiderpass E, Braaten T, Persson I, Adami HO, Lund E. Use of oral contraceptives and breast cancer risk: The Norwegian-Swedish Women's Lifestyle and Health Cohort Study. Cancer Epidemiol Biomarkers Prev 2002;11:1375-81.
60. Dumeaux V, Alsaker E, Lund E. Breast cancer and specific types of oral contraceptives: A large Norwegian cohort study. Int J Cancer 2003;105:844-50.
61. Dumeaux V, Fournier A, Lund E, Clavel-Chapelon F. Previous oral contraceptive use and breast cancer risk according to hormone replacement therapy use among postmenopausal women. Cancer Causes Control 2005;16:537-44.
62. Silvera SA, Miller AB, Rohan TE. Oral contraceptive use and risk of breast cancer among women with a family history of breast cancer: A prospective cohort study. Cancer Causes Control 2005;16:1059-63.
63. Vessey M, Painter R. Oral contraceptive use and cancer. Findings in a large cohort study, 1968-2004. Br J Cancer 2006;95:385-9.
64. Brohet RM, Goldgar DE, Easton DF, Antoniou AC, Andrieu N, Chang- Claude J, et al. Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: A report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCSCollaborating Group. J Clin Oncol 2007;25:3831-6.
65. Hannaford PC, Selvaraj S, Elliott AM, Angus V, Iversen L, Lee AJ. Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner's oral contraception study. BMJ 2007;335:651.
66. Hannaford P, Elliott A. Use of exogenous hormones by women and colorectal cancer: evidence from the Royal College of General Practitioners' Oral Contraception Study. Contraception 2005;71:95-8.
67. Lund E, Bakken K, Dumeaux V, Andersen V, Kumle M. Hormone replacement therapy and breast cancer in former users of oral contraceptives- The Norwegian Women and Cancer study. Int J Cancer 2007;121:645-8.
68. Dorjgochoo T, Shu XO, Li HL, Qian HZ, Yang G, Cai H, et al. Use of oral contraceptives, intrauterine devices and tubal sterilization and cancer risk in a large prospective study, from 1996 to 2006. Int J Cancer 2009;124:2442-9.
69. Rosenblatt KA, Gao DL, Ray RM, Nelson ZC, Wernli KJ, Li W, et al. Oral contraceptives and the risk of all cancers combined and sitespecific cancers in Shanghai. Cancer Causes Control 2009;20: 27-34.
70. Wernli KJ, Ray RM, Gao DL, De Roos AJ, Checkoway H, Thomas DB. Menstrual and reproductive factors in relation to risk of endometrial cancer in Chinese women. Cancer Causes Control 2006;17:949-55.
71. Hunter DJ, Colditz GA, Hankinson SE, Malspeis S, Spiegelman D, Chen W, et al. Oral contraceptive use and breast cancer: A prospective study of young women. Cancer Epidemiol Biomarkers Prev 2010;19:2496-502.
72. Rosenberg L, Boggs DA, Wise LA, Adams-Campbell LL, Palmer JR. Oral contraceptive use and estrogen/progesterone receptor-negative breast cancer among African American women. Cancer Epidemiol Biomarkers Prev 2010;19:2073-9.
73. Urban M, Banks E, Egger S, Canfell K, O'Connell D, Beral V, et al. Injectable and oral contraceptive use and cancers of the breast, cervix, ovary, and endometrium in black South African women: case-control study. PLoS Med 2012;9:e1001182.
74. Xu WH, Shu XO, Long J, Lu W, Cai Q, Zheng Y, et al. Relation of FGFR2 genetic polymorphisms to the association between oral contraceptive use and the risk of breast cancer in Chinese women. Am J Epidemiol 2011;173:923-31.
75. Bernholtz S, Laitman Y, Kaufman B, Paluch Shimon S, Friedman E. Cancer risk in JewishBRCA1 and BRCA2 mutation carriers: effects of oral contraceptive use and parental origin of mutation. Breast Cancer Res Treat 2011;129:557-563.
76. Marchbanks PA, Curtis KM, Mandel MG, Wilson HG, Jeng G, Folger SG, et al. Oral contraceptive formulation and risk of breast cancer. Contraception 2012;85:342-350.
77. Tryggvadottir L, Tulinius H, Eyfjord JE, Sigurvinsson T. Breast cancer risk factors and age at diagnosis: An Icelandic cohort study. Int J Cancer 2002;98:604-8.
78. Wrensch M, Chew T, Farren G, Barlow J, Belli F, Clarke C, et al. Risk factors for breast cancer in a population with high incidence rates. Breast Cancer Res 2003;5:R88-102.
79. MadeleineMM, Daling JR, Schwartz SM, Shera K, McKnight B, Carter JJ, et al. Human papillomavirus and long-term oral contraceptive use increase the risk of adenocarcinoma in situ of the cervix. Cancer Epidemiol Biomarkers Prev 2001;10:171-7.
80. Santos C, Munoz N, Klug S, Almonte M, Guerrero I, Alvarez M, et al. HPV types and cofactors causing cervical cancer in Peru. Br J Cancer 2001;85:966-71.
81. Green J, Berrington de Gonzalez A, Sweetland S, Beral V, Chilvers C, Crossley B, et al. Risk factors for adenocarcinoma and squamous cell carcinoma of the cervix in women aged 20-44 years: The UK National Case-Control Study of Cervical Cancer. Br J Cancer 2003;89:2078-86.
82. Shapiro S, Rosenberg L, Hoffman M, Kelly JP, Cooper DD, Carrara H, et al. Risk of invasive cancer of the cervix in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen oral contraceptives (South Africa). Cancer Causes Control 2003;14:485-95.
83. Shields TS, Brinton LA, Burk RD, Wang SS, Weinstein SJ, Ziegler RG, et al. A case-control study of risk factors for invasive cervical cancer among U.S. women exposed to oncogenic types of human papillomavirus. Cancer Epidemiol Biomarkers Prev 2004;13:1574-82.
84. Nojomi M, Modaresgilani M, Mozafari N, Erfany A. Cervical cancer and duration of using hormonal contraceptives. Asia-Pacific J Clin Oncol 2008;4:107-112.
85. Vanakankovit N, Taneepanichskul S. Effect of oral contraceptives on risk of cervical cancer. J Med Assoc Thai 2008;91:7-12.
86. Moreno V, Bosch FX, Munoz N, Meijer CJ, Shah KV, Walboomers JM, et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: The IARC multicentric casecontrol study. Lancet 2002;359:1085-92.
87. Hammouda D, Munoz N, Herrero R, Arslan A, Bouhadef A, Oublil M, et al. Cervical carcinoma in Algiers, Algeria: human papillomavirus and lifestyle risk factors. Int J Cancer 2005;113:483-9.
88. Levi F, Pasche C, Lucchini F, La Vecchia C. Oral contraceptives and colorectal cancer. Dig Liver Dis 2003;35:85-7.
89. Campbell PT, NewcombP, Gallinger S, Cotterchio M, McLaughlin JR. Exogenous hormones and colorectal cancer risk in Canada: Associations stratified by clinically defined familial risk of cancer. Cancer Causes Control 2007;18:723-33.
90. Long MD, Martin CF, Galanko JA, Sandler RS. Hormone replacement therapy, oral contraceptive use, and distal large bowel cancer: A population-based case-control study. Am J Gastroenterol 2010;105: 1843-50.
91. Kabat GC, Miller AB, Rohan TE. Oral contraceptive use, hormone replacement therapy, reproductive history and risk of colorectal cancer in women. Int J Cancer 2008;122:643-6.
92. Lin J, Zhang SM, Cook NR, Manson JE, Buring JE, Lee IM. Oral contraceptives, reproductive factors, and risk of colorectal cancer among women in a prospective cohort study. Am J Epidemiol 2007; 165:794-801.
93. Tsilidis KK, Allen NE, Key TJ, Bakken K, Lund E, Berrino F, et al. Oral contraceptives, reproductive history and risk of colorectal cancer in the European Prospective Investigation into Cancer and Nutrition. Br J Cancer 2010;103:1755-9.
94. Nichols HB, Trentham-Dietz A, Hampton JM, Newcomb PA. Oral contraceptive use, reproductive factors, and colorectal cancer risk: findings from Wisconsin. Cancer Epidemiol Biomarkers Prev 2005; 14:1212-8.
95. Rosenblatt KA, Gao DL, Ray RM, Nelson ZC, Thomas DB. Contraceptive methods and induced abortions and their association with the risk of colon cancer in Shanghai, China. Eur J Cancer 2004;40: 590-3.
96. Parslov M, Lidegaard O, Klintorp S, Pedersen B, Jonsson L, Eriksen PS, et al. Risk factors among young women with endometrial cancer: A Danish case-control study. Am J Obstet Gynecol 2000;182:23-9.
97. Maxwell GL, Schildkraut JM, Calingaert B, Risinger JI, Dainty L, Marchbanks PA, et al. Progestin and estrogen potency of combination oral contraceptives and endometrial cancer risk. Gynecol Oncol 2006;103:535-40.
98. Dossus L, Allen N, Kaaks R, Bakken K, Lund E, Tjonneland A, et al. Reproductive risk factors and endometrial cancer: The European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2010;127:442-51.
99. Setiawan VW, Pike MC, Kolonel LN, Nomura AM, Goodman MT, Henderson BE. Racial/ethnic differences in endometrial cancer risk: The multiethnic cohort study. Am J Epidemiol 2007;165: 262-70.
100. Tao MH, Xu WH, Zheng W, Zhang ZF, Gao YT, Ruan ZX, et al. Oral contraceptive and IUD use and endometrial cancer: A populationbased case-control study in Shanghai, China. Int J Cancer 2006; 119:2142-7.
101. Havrilesky L, Moorman P, Lowery W, Gierisch J, Coeytaux R, Peragallo Urrutia R, et al. Oral contraceptive pills as primary prevention for ovarian cancer: A systematic review and meta-analysis. Obstet Gynecol 2013;122:139-47.
102. Peragallo Urrutia R, Coeytaux R, McBroom A, Gierisch J, Havrilesky L, Moorman P, et al. Risk of acute thromboembolic events with oral contraceptive use: A systematic review and meta-analysis. Obstet Gynecol 2013;122:380-9.
103. Hankinson SE, Colditz GA, Manson JE, Willett WC, Hunter DJ, Stampfer MJ, et al. A prospective study of oral contraceptive use and risk of breast cancer (Nurses' Health Study, United States). Cancer Causes Control 1997;8:65-72.
104. Kahlenborn C, Modugno F, Potter DM, Severs WB. Oral contraceptive use as a risk factor for premenopausal breast cancer: A metaanalysis. Mayo Clin Proc 2006;81:1290-302.
105. International Collaboration of Epidemiological Studies of Cervical Cancer. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16, 573 women with cervical cancer and 35, 509 women without cervical cancer from 24 epidemiological studies. Lancet 2007;370:1609-21.
106. Fernandez E, La Vecchia C, Balducci A, Chatenoud L, Franceschi S, Negri E. Oral contraceptives and colorectal cancer risk: A metaanalysis. Br J Cancer 2001;84:722-7.
107. Grimes DA, Economy KE. Primary prevention of gynecologic cancers. Am J Obstet Gynecol 1995;172:227-35.
108. Schlesselman JJ. Risk of endometrial cancer in relation to use of combined oral contraceptives. A practitioner's guide to meta-analysis. Hum Reprod 1997;12:1851-63.